A news item involving Allergan was featured on Wikipedia's Main Page in the In the news section on 6 April 2016. |
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
This article has been
mentioned by a media organization:
|
The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
|
I have found that the FML Forte eye drop used to used to treat eye PRK and Lasik post operative side affects is at least 10 drops short on the first two bottles that I purchased from Allergan Pharmaceuticals. It is $250.00 U.S. dollars per bottle. They use the metric conversion table to fill their bottles which their Quality Assurance Section stated was 15 drops per ML. It is actually suppose to be 15.4 drops per ML using the metric table. The U.S. conversion table is 20 drops per ML. If you call their Quality Assurance Section they will say they put extra drops in each bottle. They will of course deny that their bottles are short any drops. PRK and Lasik is a very popular eye corrective surgery in the United States. Allergan Stock is $223.00 per share. — Preceding unsigned comment added by 75.71.10.154 ( talk) 15:09, 26 April 2016 (UTC)
Interesting, and quite factual analysis that should be further pursued.-- Wikipietime ( talk) 15:32, 9 September 2017 (UTC)
stub, was bought by Allergan. Natureium ( talk) 20:45, 26 January 2017 (UTC)
St. Regis Mohawk Reservation has come online for protection of ip.
Casinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents
-- Wikipietime ( talk) 15:30, 9 September 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. |
On behalf of Allergan, and as part of my work at Beutler Ink, I am looking to make some updates and improvements to this Wikipedia article. I'd like to start with a very straightforward request. Currently, the "Key products" section is almost entirely unsourced. There are two inline citations in the section, both of which direct readers to the Allergan website, and I think we can all agree this is not ideal. I've found sources to verify connections between Allergan and each of the products currently listed in this section. I believe they are appropriate for Wikipedia, and I've not made other major content changes. I'm merely attempting to improve the article's integrity by adding sourcing. Below, I offer a rendering of an updated "Key products" section and markup for editor review:
Rendering of proposed "Key products" section
|
---|
|
References
|
---|
References
|
Markup
|
---|
{{columns-list|colwidth=30em| |
I'm seeking a volunteer to review the proposed markup and copy over appropriately. Happy to answer any questions here or on my user talk page. Thanks! Inkian Jason ( talk) 20:16, 12 January 2018 (UTC)
@ Jytdog: I realized I didn't follow up here, apologies for that. While a listing of products is understandably not appropriate, I assume the article should mention something about the products in non-listing, prose form. I'm working on a draft that will do this and will work to ensure it meets guidelines. For now, a short mention of just the notable products is included in the proposed Corporate overview section below to illustrate the type of products that the company produces. Inkian Jason ( talk) 20:55, 1 March 2018 (UTC)
This edit request by an editor with a conflict of interest has now been answered. |
Hello! I am back with an additional edit request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink. For this request, I propose three specific updates to the article's infobox:
I will have additional requests for updating and improving this article, but this request is enough for volunteer editors to review for now. Please let me know if you have any questions. Thank you! Inkian Jason ( talk) 21:38, 1 February 2018 (UTC)
I am back with an additional request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink.
Currently, this article jumps straight into a complicated, six-sectioned corporate history. I think the article could benefit from starting with a "Corporate overview" section, providing a snapshot of the company before diving right into history details. Based on similar overview sections for company articles, I propose the following, which includes mention of the company's formation, headquarters (and second major operations hub), the number of employees and revenue for 2016, the name of the current chief executive, and a brief summary of Allergan's products and business model:
Extended content
|
---|
Allergan was created in 2015 when the company formerly known as Actavis, Plc acquired Allergan, Inc. and continued to use Allergan's name. [1] [2] Allergan is based in Dublin and has major operations in Irvine. [3] [4] In 2016, the company had 16,700 employees and earned $14.57 billion. [5] Brent Saunders serves as Allergan's chief executive officer (CEO). [6] In 2015, prior to Teva Pharmaceutical Industries' purchase of the company's generic drugs business, Allergan offered approximately 1,000 products, including branded generics, over-the-counter drugs, and generic forms of popular pharmaceutical drugs. [3] Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals. [3] Some of the company's products include: Avycaz, [7] Botox [8] CoolSculpting, [9] Dalvance, [10] Juvéderm, [11] Linzess, [12] Viberzi, [13] and Vraylar. [14] |
References
|
---|
References
|
Markup
|
---|
==Corporate overview== In 2015, prior to [[Teva Pharmaceutical Industries]]' purchase of the company's [[generic drug]]s business, Allergan offered approximately 1,000 products, including branded generics, [[over-the-counter drugs]], and generic forms of popular [[pharmaceutical drug]]s.<ref name="ToBuy">{{cite news|title=Teva to Buy Allergan Generics for $40.5 Billion|url=https://www.wsj.com/articles/teva-to-buy-allergan-generics-for-40-5-billion-1437988044|accessdate=14 December 2017|work=[[The Wall Street Journal]]|date=27 July 2015|first1=Jonathan D.|last1=Rockoff|first2=Dana|last2=Mattioli|first3=Liz|last3=Hoffman|publisher=[[News Corp]] ([[Dow Jones & Company]])|issn=0099-9660|oclc=781541372}}</ref> Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals.<ref name=ToBuy/> Some of the company's products include: [[Ceftazidime/avibactam|Avycaz]],<ref>{{Cite news|url=http://www.pharmatimes.com/news/us_regulators_expand_use_of_allergans_antibiotic_1185496|title=US regulators expand use of Allergan's antibiotic|date=31 January 2017|accessdate=12 January 2018|work= PharmaTimes|first=Selina|last=McKee}}</ref> [[Botox]]<ref>{{Cite journal|url=https://www.newyorker.com/business/currency/actavis-allergan-botox-sale|first=Vauhini|last=Vara|date=18 November 2014|accessdate=12 January 2018|title=Billions and Billions for Botox|work=[[The New Yorker]]|publisher=[[Condé Nast]]|issn=0028-792X|oclc=320541675}}</ref> [[Cryolipolysis|CoolSculpting]],<ref>{{cite news|title=Allergan is buying CoolSculpting provider Zeltiq for $2.48 billion|url=http://www.latimes.com/business/la-fi-allergan-zeltiq-coolsculpting-20170213-story.html|accessdate=25 January 2018|work=Los Angeles Times|date=13 February 2017}}</ref> [[Dalbavancin|Dalvance]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/single-dose-treatment-option-approved-for-skin-infection-drug-dalvance|title=Single-Dose Treatment Option Approved for Skin Infection Drug Dalvance|date=28 January 2016|accessdate=12 January 2018|first=Krystle|last=Vermes|website=Pharmacy Times}}</ref> [[Juvéderm]],<ref>{{Cite journal|url=https://www.ocbj.com/news/2017/aug/03/allergan-2q-strong-raises-guidance-performance/|title=Allergan Q2 Strong, Raises Guidance|date=3 August 2017|accessdate=12 January 2018|first=Sherry|last=Hsieh|work=[[Orange County Business Journal]]}}</ref> [[Linaclotide|Linzess]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/fda-approves-new-dose-for-chronic-idiopathic-constipation-drug|work=Pharmacy Times|title=FDA Approves New Dose for Chronic Idiopathic Constipation Drug|date=27 January 2017|first=Jennifer|last=Barrett|accessdate=12 January 2018}}</ref> [[Eluxadoline|Viberzi]],<ref>{{Cite news|url=https://www.mediapost.com/publications/article/272794/allergan-launches-campaign-for-viberzi.html|title=Allergan Launches Campaign For Viberzi|accessdate=12 January 2018|date=5 April 2016|first=Nina|last=Lentini|work=Marketing Daily|publisher=[[MediaPost Communications]]}}</ref> and [[Cariprazine|Vraylar]].<ref>{{cite news|title=Brief: Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia|url=https://www.reuters.com/article/brief-allergan-receives-fda-approval-for/brief-allergan-receives-fda-approval-for-use-of-vraylar-in-maintenance-treatment-of-schizophrenia-idUSASB0BTG0|accessdate=25 January 2018|publisher=Reuters|date=12 November 2017}}</ref> |
I don't think these claims are very controversial to include, not to mention they help verify some of the (currently unsourced) content displayed in the article's infobox. Note: The SEC citation included in the rendering and markup above, which I included for easier editor review, is already used in the article. In order to avoid duplication, I suggest naming the SEC source and re-calling this citation within the proposed overview section.
I will not be editing the article directly given my conflict of interest, and I'm seeking help from neutral editors to review and implement this content appropriately. @ XyZAn: I see you have made quite a few contributions to the article in the past, and have an interest in biotech and pharmaceutical companies. Would you consider taking a look at this proposed article improvement? I can address questions or concerns here, and thanks for any help in advance. Inkian Jason ( talk) 17:01, 6 February 2018 (UTC)
The formal name of Allergan is Allergan plc, which I propose this article title should be moved to. Allergan plc is the title the SEC gives Allergan on their 10=K, and also legally connects Allergan to being an Irish company (which it is). It also avoids confusion with the older Allergan, Inc. etc. Britishfinance ( talk)
A news item involving Allergan was featured on Wikipedia's Main Page in the In the news section on 6 April 2016. |
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
This article has been
mentioned by a media organization:
|
The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
|
I have found that the FML Forte eye drop used to used to treat eye PRK and Lasik post operative side affects is at least 10 drops short on the first two bottles that I purchased from Allergan Pharmaceuticals. It is $250.00 U.S. dollars per bottle. They use the metric conversion table to fill their bottles which their Quality Assurance Section stated was 15 drops per ML. It is actually suppose to be 15.4 drops per ML using the metric table. The U.S. conversion table is 20 drops per ML. If you call their Quality Assurance Section they will say they put extra drops in each bottle. They will of course deny that their bottles are short any drops. PRK and Lasik is a very popular eye corrective surgery in the United States. Allergan Stock is $223.00 per share. — Preceding unsigned comment added by 75.71.10.154 ( talk) 15:09, 26 April 2016 (UTC)
Interesting, and quite factual analysis that should be further pursued.-- Wikipietime ( talk) 15:32, 9 September 2017 (UTC)
stub, was bought by Allergan. Natureium ( talk) 20:45, 26 January 2017 (UTC)
St. Regis Mohawk Reservation has come online for protection of ip.
Casinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents
-- Wikipietime ( talk) 15:30, 9 September 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. |
On behalf of Allergan, and as part of my work at Beutler Ink, I am looking to make some updates and improvements to this Wikipedia article. I'd like to start with a very straightforward request. Currently, the "Key products" section is almost entirely unsourced. There are two inline citations in the section, both of which direct readers to the Allergan website, and I think we can all agree this is not ideal. I've found sources to verify connections between Allergan and each of the products currently listed in this section. I believe they are appropriate for Wikipedia, and I've not made other major content changes. I'm merely attempting to improve the article's integrity by adding sourcing. Below, I offer a rendering of an updated "Key products" section and markup for editor review:
Rendering of proposed "Key products" section
|
---|
|
References
|
---|
References
|
Markup
|
---|
{{columns-list|colwidth=30em| |
I'm seeking a volunteer to review the proposed markup and copy over appropriately. Happy to answer any questions here or on my user talk page. Thanks! Inkian Jason ( talk) 20:16, 12 January 2018 (UTC)
@ Jytdog: I realized I didn't follow up here, apologies for that. While a listing of products is understandably not appropriate, I assume the article should mention something about the products in non-listing, prose form. I'm working on a draft that will do this and will work to ensure it meets guidelines. For now, a short mention of just the notable products is included in the proposed Corporate overview section below to illustrate the type of products that the company produces. Inkian Jason ( talk) 20:55, 1 March 2018 (UTC)
This edit request by an editor with a conflict of interest has now been answered. |
Hello! I am back with an additional edit request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink. For this request, I propose three specific updates to the article's infobox:
I will have additional requests for updating and improving this article, but this request is enough for volunteer editors to review for now. Please let me know if you have any questions. Thank you! Inkian Jason ( talk) 21:38, 1 February 2018 (UTC)
I am back with an additional request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink.
Currently, this article jumps straight into a complicated, six-sectioned corporate history. I think the article could benefit from starting with a "Corporate overview" section, providing a snapshot of the company before diving right into history details. Based on similar overview sections for company articles, I propose the following, which includes mention of the company's formation, headquarters (and second major operations hub), the number of employees and revenue for 2016, the name of the current chief executive, and a brief summary of Allergan's products and business model:
Extended content
|
---|
Allergan was created in 2015 when the company formerly known as Actavis, Plc acquired Allergan, Inc. and continued to use Allergan's name. [1] [2] Allergan is based in Dublin and has major operations in Irvine. [3] [4] In 2016, the company had 16,700 employees and earned $14.57 billion. [5] Brent Saunders serves as Allergan's chief executive officer (CEO). [6] In 2015, prior to Teva Pharmaceutical Industries' purchase of the company's generic drugs business, Allergan offered approximately 1,000 products, including branded generics, over-the-counter drugs, and generic forms of popular pharmaceutical drugs. [3] Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals. [3] Some of the company's products include: Avycaz, [7] Botox [8] CoolSculpting, [9] Dalvance, [10] Juvéderm, [11] Linzess, [12] Viberzi, [13] and Vraylar. [14] |
References
|
---|
References
|
Markup
|
---|
==Corporate overview== In 2015, prior to [[Teva Pharmaceutical Industries]]' purchase of the company's [[generic drug]]s business, Allergan offered approximately 1,000 products, including branded generics, [[over-the-counter drugs]], and generic forms of popular [[pharmaceutical drug]]s.<ref name="ToBuy">{{cite news|title=Teva to Buy Allergan Generics for $40.5 Billion|url=https://www.wsj.com/articles/teva-to-buy-allergan-generics-for-40-5-billion-1437988044|accessdate=14 December 2017|work=[[The Wall Street Journal]]|date=27 July 2015|first1=Jonathan D.|last1=Rockoff|first2=Dana|last2=Mattioli|first3=Liz|last3=Hoffman|publisher=[[News Corp]] ([[Dow Jones & Company]])|issn=0099-9660|oclc=781541372}}</ref> Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals.<ref name=ToBuy/> Some of the company's products include: [[Ceftazidime/avibactam|Avycaz]],<ref>{{Cite news|url=http://www.pharmatimes.com/news/us_regulators_expand_use_of_allergans_antibiotic_1185496|title=US regulators expand use of Allergan's antibiotic|date=31 January 2017|accessdate=12 January 2018|work= PharmaTimes|first=Selina|last=McKee}}</ref> [[Botox]]<ref>{{Cite journal|url=https://www.newyorker.com/business/currency/actavis-allergan-botox-sale|first=Vauhini|last=Vara|date=18 November 2014|accessdate=12 January 2018|title=Billions and Billions for Botox|work=[[The New Yorker]]|publisher=[[Condé Nast]]|issn=0028-792X|oclc=320541675}}</ref> [[Cryolipolysis|CoolSculpting]],<ref>{{cite news|title=Allergan is buying CoolSculpting provider Zeltiq for $2.48 billion|url=http://www.latimes.com/business/la-fi-allergan-zeltiq-coolsculpting-20170213-story.html|accessdate=25 January 2018|work=Los Angeles Times|date=13 February 2017}}</ref> [[Dalbavancin|Dalvance]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/single-dose-treatment-option-approved-for-skin-infection-drug-dalvance|title=Single-Dose Treatment Option Approved for Skin Infection Drug Dalvance|date=28 January 2016|accessdate=12 January 2018|first=Krystle|last=Vermes|website=Pharmacy Times}}</ref> [[Juvéderm]],<ref>{{Cite journal|url=https://www.ocbj.com/news/2017/aug/03/allergan-2q-strong-raises-guidance-performance/|title=Allergan Q2 Strong, Raises Guidance|date=3 August 2017|accessdate=12 January 2018|first=Sherry|last=Hsieh|work=[[Orange County Business Journal]]}}</ref> [[Linaclotide|Linzess]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/fda-approves-new-dose-for-chronic-idiopathic-constipation-drug|work=Pharmacy Times|title=FDA Approves New Dose for Chronic Idiopathic Constipation Drug|date=27 January 2017|first=Jennifer|last=Barrett|accessdate=12 January 2018}}</ref> [[Eluxadoline|Viberzi]],<ref>{{Cite news|url=https://www.mediapost.com/publications/article/272794/allergan-launches-campaign-for-viberzi.html|title=Allergan Launches Campaign For Viberzi|accessdate=12 January 2018|date=5 April 2016|first=Nina|last=Lentini|work=Marketing Daily|publisher=[[MediaPost Communications]]}}</ref> and [[Cariprazine|Vraylar]].<ref>{{cite news|title=Brief: Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia|url=https://www.reuters.com/article/brief-allergan-receives-fda-approval-for/brief-allergan-receives-fda-approval-for-use-of-vraylar-in-maintenance-treatment-of-schizophrenia-idUSASB0BTG0|accessdate=25 January 2018|publisher=Reuters|date=12 November 2017}}</ref> |
I don't think these claims are very controversial to include, not to mention they help verify some of the (currently unsourced) content displayed in the article's infobox. Note: The SEC citation included in the rendering and markup above, which I included for easier editor review, is already used in the article. In order to avoid duplication, I suggest naming the SEC source and re-calling this citation within the proposed overview section.
I will not be editing the article directly given my conflict of interest, and I'm seeking help from neutral editors to review and implement this content appropriately. @ XyZAn: I see you have made quite a few contributions to the article in the past, and have an interest in biotech and pharmaceutical companies. Would you consider taking a look at this proposed article improvement? I can address questions or concerns here, and thanks for any help in advance. Inkian Jason ( talk) 17:01, 6 February 2018 (UTC)
The formal name of Allergan is Allergan plc, which I propose this article title should be moved to. Allergan plc is the title the SEC gives Allergan on their 10=K, and also legally connects Allergan to being an Irish company (which it is). It also avoids confusion with the older Allergan, Inc. etc. Britishfinance ( talk)